Related references
Note: Only part of the references are listed.Cell-free DNA analysis in current cancer clinical trials: a review
M. Cisneros-Villanueva et al.
BRITISH JOURNAL OF CANCER (2022)
All roads lead to targeted diffuse large B-cell lymphoma approaches
Peng -Peng Xu et al.
CANCER CELL (2022)
Circulating Tumor DNA in Lymphoma: Principles and Future Directions
Mark Roschewski et al.
BLOOD CANCER DISCOVERY (2022)
Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA
Steven Le Gouill et al.
BLOOD (2021)
A Probabilistic Classification Tool for Genetic Subtypes of Diffuse Large B Cell Lymphoma with Therapeutic Implications
George W. Wright et al.
CANCER CELL (2020)
Circulating tumor DNA and liquid biopsy in oncology
David W. Cescon et al.
NATURE CANCER (2020)
Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes
Bjoern Chapuy et al.
NATURE MEDICINE (2018)
Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma
David M. Kurtz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Enhanced detection of circulating tumor DNA by fragment size analysis
Florent Mouliere et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Direct detection of early-stage cancers using circulating tumor DNA
Jillian Phallen et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
Diffuse large B-cell lymphoma genotyping on the liquid biopsy
Davide Rossi et al.
BLOOD (2017)
Randomized Trial Comparing R-CHOP Versus High-Dose Sequential Chemotherapy in High-Risk Patients With Diffuse Large B-Cell Lymphomas
Sergio Cortelazzo et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA
Florian Scherer et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
The Long and Short of Circulating Cell-Free DNA and the Ins and Outs of Molecular Diagnostics
Peiyong Jiang et al.
TRENDS IN GENETICS (2016)
Randomized Comparison of Gemcitabine, Dexamethasone, and Cisplatin Versus Dexamethasone, Cytarabine, and Cisplatin Chemotherapy Before Autologous Stem-Cell Transplantation for Relapsed and Refractory Aggressive Lymphomas: NCIC-CTG LY.12
Michael Crump et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
Autologous Transplantation as Consolidation for Aggressive Non-Hodgkin's Lymphoma
Patrick J. Stiff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Interim [18F]Fluorodeoxyglucose Positron Emission Tomography Scan in Diffuse Large B-Cell Lymphoma Treated With Anthracycline-Based Chemotherapy Plus Rituximab
Violaine Safar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma
Rene -Olivier Casasnovas et al.
BLOOD (2011)
First-line rituximab (R) high-dose therapy (R-HDT) versus R-CHOP14 for young adults with diffuse large B-cell lymphoma: Preliminary results of the GOELAMS 075 prospective multicenter randomized trial
S. Le Gouill et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial
Christian Recher et al.
LANCET (2011)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cell-free circulating DNA in Hodgkin's and non-Hodgkin's lymphomas
S. Hohaus et al.
ANNALS OF ONCOLOGY (2009)
[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma:: an early prognostic tool for predicting patient outcome
C Haioun et al.
BLOOD (2005)
Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem-cell support
N Milpied et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma
C Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma:: Final analysis of the prospective LNH87-2 protocol -: A Groupe d'Etude des Lymphomes de l'Adulte Study
C Haioun et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
Share Paper
